Help with Hypoglycemia

The DCCT and other studies highlight the benefit of tight glycemic control in people with type 1 and type 2 diabetes.2 The challenge continues to be achieving this tight control without increasing the incidence of hypoglycemia. By displaying the direction and rate of glucose change, CGM provides greater insight than just a glucose value at a single point in time. Real time glucose trends and alerts can help your patients respond proactively before their glucose drops too low. CGM is the tool that helps your patients achieve tight control.1

CGM helps more adults get to A1c Goals (<7%) without severe hypoglycemia1

In a recent JDRF study, more adults were able to achieve the ADA target A1c goal without incidence of severe hypoglycemia (<50mg/dL) when using CGM.1

CGM use proven to sustain hypoglycemia reduction for 12 months4

Over the 12 months of the JDRF study, CGM reduced time spent in the hypoglycemic range (<60 mg/dL) for subjects with a high A1c and those with well-controlled A1c, demonstrating that CGM can be beneficial for patients across all spectrums of glycemic control.3,4

Accuracy Where it Matters Most

A common side effect of intensive diabetes management is hypoglycemia. Hypoglycemia can not only be debilitating and have deleterious consequences but can diminish counterregulatory hormone response and induce hypoglycemia unawareness, resulting in a cycle of hypoglycemia and an increased risk of subsequent severe hypoglycemia. Even with the use of insulin pumps and long-acting insulin analogs, significant nocturnal hypoglycemia is common.7

CGM Performance in the Hypoglycemia Range12, 13

With its unique severe hypoglycemia alarm at 55mg/dL, excellent performance in the hypoglycemia range and consistent accuracy over time, the Dexcom® SEVEN® PLUS is leading the way in providing your patients reliable glucose information when it matters most.13

Not All CGMs are Created Equal - It’s All About The Technology

Dexcom’s ability to deliver accurate performance drives from our historical roots in developing long-term implantable sensor technology.

  • Sensor Geometry and Membrane Technology

    Dexcom’s round platinum electrode along with a multi-layered membrane technology results in a sensor that delivers reliable performance, accuracy in the hypoglycemia range, and contributes to minimum lag time.8
  1. Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. Continuous Glucose Monitoring and Intensive Treatment of Type 1 Diabetes. N Engl J Med. 2008;359(14):1464-1476.
  2. U.K. Prospective Diabetes Study Group, Intensive Blood-Glucose Control with Sulphonylureas or Insulin Compared with Conventional Treatment and Risk of Complications in Patients with Type 2 Diabetes. Lancet, 1998;352:837-853.
  3. Bergenstal RM, Tamborlane WV, Ahmann A, Buse JB et al. Effectiveness of Sensor-Augmented Insulin Pump Therapy in Type 1 Diabetes. New England Journal of Medicine, June 29, 2010.
  4. Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. Sustained Benefits of Continuous Glucose Monitoring on HbA1c, Glucose Profiles, and Hypoglycemia in Adults with Type 1 Diabetes. Diabetes Care Published Ahead of Print, published on line August 12, 2009.
  5. Kamath A et al. Analysis of Time Lags and Other Sources of Error of the Dexcom SEVEN Continuous Glucose Monitor. Diabetes Technology and Therapeutics, Vol 11, No. 11, 2009.
  6. Garg S, Jovanovic L. Relationship of Fasting and Hourly Blood Glucose Levels to HbA1c Values: safety, accuracy and improvements in glucose profiles obtained using a 7-day continuous glucose sensor. Diabetes Care, 2006;29(12):2644-2649.
  7. Cox DJ, Gonder-Frederick L, Ritterband L, Clarke W, Kovatchev BP. Prediction of severe hypoglycemia. Diabetes Care. 2007 Jun:30(6):1370-3. Epub 2007 Mar 15.
  8. Bailey T, Zisser H, Chang A. New Features and Performance of a Next-Generation SEVEN-Day Continuous Glucose Monitoring System with Short Lag Time. Diabetes Technology & Therapeutics, 2009, Vol 11. No. 12:749-755.
  9. Weinstein RL, et al. Diabetes Care, 2007;30(5):1125-3110.
  10. Medtronic only reports overall Mean ARD data.
  11. Dexcom SEVEN PLUS Summary of Safety and Effectiveness Data (SSED), 2008.
  12. Based on manufacturer user’s guides. FreeStyle Navigator, 2008. Medtronic Paradigm REAL-Time Revel, 2009.
  13. Based on manufacturer user’s guides. Dexcom SEVEN PLUS, 2008.